David A. Siegel Angion Biomedica Corp. Transaction History

Two Sigma Advisers, LP

  • $42.5 Billion
  • Q1 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022
SELL
$1.72 - $2.96 $71,896 - $123,728
-41,800 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$2.35 - $9.95 $98,230 - $415,909
41,800 New
41,800 $121,000

About Angion Biomedica Corp.

ANGN Quotes by TradingView
  • Ticker ANGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,113,300
  • Description
  • Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primaril...
More about ANGN
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email